Key result
Finerenone cuts composite kidney outcomes ~18% compared to placebo.
Why the study?
Cardiovascular death risk escalates with multiple risk factors in patients with diabetes over 10 years, and intensive risk factor reduction may reduce events.
Answers are grounded in this paper and cite their sources.
specifically, cholesterol, cigarette smoking status, and systolic blood pressure.It is interesting to note that age adjusted cardiovascular death risk per 10,000 person years escalates at a near hyperbolic response in patients with multiple of these aforementioned risk factors after suffering with diabetes over 10years.6 Likewise, the converse may apply where intensive treatment with reduction of risk factors mentioned lit led to significant reduction in cumulative death and cardiovascular events as was demonstrated in the historic STENO 2 trial.
No takes yet. Share an insight, caveat, or question.
Morales et al. (2021) conducted a review in Diabetic kidney disease (n=5,734). Finerenone vs. placebo was evaluated on Time to kidney failure, sustained greater than or equal to 40% decrease in eGFR from baseline or renal death (18% reduction, p=0.0014).
Synapse has enriched 10 related papers. Consider them for comparative context: